28
Oct
2025
Gan & Lee Pharmaceuticals
Exhibitor at CPHI Frankfurt 2025 stand 4.1B16, Finished Dosage Formulations
About Us
Categories
-
CN
-
2021On CPHI since
Event information
CPHI Frankfurt 2025
-
28 Oct 2025 - 30 Oct 2025
-
Messe, Frankfurt
-
Visit us at stand 4.1B16, Finished Dosage Formulations
Products Featured at CPHI Frankfurt 2025
-
Product Basalin®(insulin glargine injection)
Basalin® is an insulin glargine injection developed and produced independently by Gan & Lee Pharmaceuticals. It was launched in China in 2005 and has been approved in almost 20 countries globally. As a long-acting biosimilar insulin, Basalin® is able to stablely control human blood sugar within 24... -
Product GanleeFine®(pen injeciton needle)
GanleeFine™ is pen needle for single use, collaborately used with insulin pen or prefilled pen for insulin injection. GanleeFine™ has 5 specifications including 0.30x6mm/30G, 0.30x8mm/30G, 0.25x6mm/31G, 0.25x8mm/31G and 0.23x4mm/32G, which can meet different people's injection needs. -
Product GanleePen™(reusable insulin pen)
GanleePen is a reusable insulin pen produced by Gan & Lee's wholly-owned subsidiary, Gangan Medical Technology Co., Ltd. It has user-friendly design, big dose window, precise dose and clear reminder for dose adjustment. In addition, GanleePen is made of high-quality and reusable materials. The color of... -
Product Prandilin®
Prandilin® is an insulin lispro injection developed and produced independently by Gan & Lee Pharmaceuticals. It was launched in China in 2007. As a fast-acting biosimilar insulin, Prandilin® is able to rapidly control human blood sugar 15-20mins after injection before a meal for the treatment of d... -
Product Prandilin®25
Prandilin®25 is a premix insulin lispro suspension developed and produced independently by Gan & Lee Pharmaceuticals. It was launched in China in 2014. As a fast-acting biosimilar insulin, Prandilin®25 is able to rapidly and stablely control human blood sugar 15-20mins after injection before a mea... -
Product Rapilin™
Rapilin™ is insulin aspart injection developed and produced independently by Gan & Lee Pharmaceuticals. It was approved in China in 2020. As a fast-acting biosimilar insulin, Rapilin™ is able to rapidly control human blood sugar 5-10 mins after injection before or between or after a meal for the t...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance